Obesity

Politics John Wilkerson

STAT Plus: Medicare already covers GLP-1s for half of seniors with obesity, new report finds

Pharmalot Ed Silverman

STAT Plus: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

STAT Plus: Biden’s health care AI czar, a new obesity company, and its dealmaking CEO

Adam's Take Adam Feuerstein

STAT Plus: Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?

Biotech Allison DeAngelis

STAT Plus: $400 million for an obesity drug startup? A new venture is a sign of the times

Biotech Elaine Chen

STAT Plus: An obesity startup wastes no time: With drugs in early testing, Metsera lines up manufacturing

Pharma Andrew Joseph

STAT Plus: Roche seeks to project confidence on its obesity drugs — and sees room to make its mark

Morning Rounds Brittany Trang

A big week for rats, genetics of picky eating, and research misconduct rules

Health Isabella Cueto and Theresa Gaffney

Intermittent fasting for teens? Obesity study finds benefits but only under careful supervision

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Corbus shares will soar or dive soon. Here’s why

In the Lab Megan Molteni and Elaine Chen

Long-overlooked scientist shares Lasker Award with other GLP-1 researchers

Biotech Elaine Chen

STAT Plus: Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster

Exclusive Kate Raphael

Pediatricians’ obesity guidelines rest on shaky evidence about eating disorder risks

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids

Morning Rounds Theresa Gaffney

A presidential debate, GLP-1s for kids, and ultra-processed foods research

Health Nicholas Florko

How a government scientist is pushing to supersize research into ultra-processed foods

Health Elaine Chen and Elizabeth Cooney

Obesity drug worked in children ages 6 to 12, study says, raising hopes and concerns

First Opinion Jeffrey Flier

STAT Plus: How Pfizer ended up passing on my GLP-1 work back in the early ’90s

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

Summit’s upcoming cancer results, Recursion’s mixed data, and a new co-host

Health Elaine Chen and Allison DeAngelis

STAT Plus: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target

Pharma Andrew Joseph

STAT Plus: At major cardiology conference, Wegovy’s the word

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy

Morning Rounds Theresa Gaffney

Is the GLP-1 party running down for Hims, and a study for the weekend

First Opinion Sophia Hua

A harm-reduction approach to eating out

The Readout LOUD Adam Feuerstein, Elaine Chen, and Allison DeAngelis

Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

Biotech Elaine Chen

STAT Plus: Lilly’s Zepbound slashed risk of developing diabetes

Pharma Andrew Joseph

STAT Plus: Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report